1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Novo Eyes Global-First Japan Approval For Concizumab

First Filing For Hemophila A/B Candidate

 
• By Lisa Takagi

Novo Nordisk has filed for the approval of its hemophilia A/B contender concizumab in Japan, which could become the first market globally for the TFPI inhibitor. The company sees dosing convenience as a potential strong advantage in the market, where there are relatively few options for hemophilia B available.

Concizumab can provide a new option for hemophilia A and B, Novo Nordisk says
Pen-Shaped Injector One Differentiator For Concizumab? • Source: Shutterstock

Novo Nordisk A/S's filing for the approval of concizumab for hemophilia A and B in Japan positions the country as potentially the first to grant an approval to the novel anti-tissue factor pathway inhibitor (TFPI). The Danish firm said in July it is currently planning a submission in the later half of 2022 in the US and in 2023 in the UK and EU.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia